Helus Pharma Inc. (HELP)
HELP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 40-F/A (ifrs-full:Revenue), fiscal year ended 2022-03-31, https://www.sec.gov/Archives/edgar/data/1833141/000162828022019311/0001628280-22-019311-index.htm. Net income: SEC 40-F/A (ifrs-full:ProfitLoss), fiscal year ended 2022-03-31. Converted from CAD at 1.4258 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | HELP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001833141 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | BC |
Financials · 2021
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$47.4M |
| Operating income | Not in SEC XBRL data |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $37.6M |
| Total assets | $59.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Reported in CAD; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 40-F 2026-06-29 |
| Cash and burn | $157.3M cash; operating cash flow -$33.3M a quarter. | Report 2026-03-31 |
| Shares outstanding | 51,631,804 (2026-03-31); 21,601,208 a year earlier; 195,328,733 three years earlier. 3y figure adjusted for splits (1-for-38 overall); the newest SEC cover-page count is from 2026-03-31; shares issued since then are not in these figures. | Cover page 2026-03-31 |
| Reverse splits, 3 years | 1; latest 1-for-38 on 2024-09-19 | Source 2024-09-19 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25 filed | 25 2026-01-02 |
| Auditor | Zeifmans LLP, Toronto, Canada | PCAOB Form AP 2026-07-21 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $8.4M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-03-31 | Not filed | -$148.0M | -$133.3M | $157.3M | No debt tags | Needs four quarters | 40-F 2026-06-29 |
| FY 2025 2025-03-31 | Not filed | -$113.1M | -$101.3M | $135.0M | No debt tags | Needs four quarters | 40-F 2025-07-01 |
| FY 2024 2024-03-31 | Not filed | -$78.1M | -$68.9M | $209.0M | No debt tags | Needs four quarters | 40-F 2025-07-01 |
| FY 2023 2023-03-31 | Not filed | -$47.5M | -$47.4M | $16.6M | No debt tags | Needs four quarters | 40-F 2024-06-26 |
| FY 2022 2022-03-31 | $0 | -$67.6M | -$45.2M | $53.6M | No debt tags | $0 | 40-F/A 2022-07-22 |
| FY 2021 2021-03-31 | $864K | -$32.2M | -$19.0M | $64.0M | No debt tags | $864K | 40-F/A 2022-07-22 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 40-F | 2026-06-29 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 461 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.0% |
| 1 month | -15.5% |
| 3 months | -22.5% |
| Year to date | +8.4% |
| 1 year | +49.3% |
| From 52-week high | -36.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| EVO | Evotec SE | $1.56 | -1.27% | $555.0M |
| WVE | Wave Life Sciences Inc. | $2.87 | -8.31% | $566.0M |
| ZVRA | Zevra Therapeutics Inc. | $9.25 | +1.87% | $550.4M |
| ACRS | Aclaris Therapeutics Inc. | $3.60 | -8.04% | $571.8M |
| CLYM | Climb Bio Inc. | $9.94 | -4.05% | $583.9M |
| INDP | Indaptus Therapeutics Inc. | $3.45 | +8.83% | $529.9M |
| AVBP | ArriVent BioPharma Inc. | $11.56 | -11.15% | $597.9M |
| CBIO | Crescent Biopharma Inc. | $13.50 | -4.59% | $525.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier